Answers are grounded in this paper and cite their sources.
LISWT in patients with ED unresponsive to PDE5i treatment was effective and safe in 60% of patients treated. The efficacy response was maintained for 12 months in most patients.
No takes yet. Share an insight, caveat, or question.
Bechara et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: